Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings. Issue 3 (18th March 2019)

• Record Type: Journal Article
• Authors: Kawahara, Takashi; Ninomiya, Sahoko; Miyoshi, Yasuhide; Yao, Masahiro; Uemura, Hiroji
• Is Part Of: IJU case reports. Volume 2:Issue 3(2019)
• Page Start: 143
• Page End: 145
• Publication Date: 2019-03-18
• Subjects: dosage form -- enzalutamide -- enzalutamide capsule -- enzalutamide tablet; Urology -- Periodicals; Genitourinary organs -- Periodicals; Electronic journals; Periodicals; 616.6
• DOI: 10.1002/iju5.12062
• Languages: English
• ISSNs: 2577-171X

Abstract

Abstract : Introduction: In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet. Case presentation: A 76‐year‐old man was initially referred to our hospital for the further examination of his elevated prostate‐specific antigen level (3664.0 ng/mL). He had developed castration‐resistant prostate cancer 10 months after initial treatment. Treatment with enzalutamide (capsule form) was subsequently initiated. In June 2018, drug form of enzalutamide was changed from a capsule to a tablet. After switching to an enzalutamide tablet, his prostate‐specific antigen level decreased significantly from 493.0 to 26.5 ng/mL. Conclusion: While the reason for this prostate‐specific antigen response is unclear, changing the enzalutamide form from a capsule to a tablet may have improved the adherence of drug intake and thereby resulted in castration‐resistant prostate cancer control.